Pneumococcal vaccines: an update on current strategies

D Bogaert, PWM Hermans, PV Adrian, HC Rümke… - Vaccine, 2004 - Elsevier
Streptococcus pneumoniae is a major cause of morbidity and mortality in infants, children and
the elderly. Despite the availability of excellent antimicrobial therapy and adequate health …

Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.

H Van Loveren, JG Van Amsterdam… - Environmental …, 2001 - ehp.niehs.nih.gov
In laboratory animals, an adequate way to assess effects of environmental exposures on the
immune system is to study effects on antigen-specific immune responses, such as after …

Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children

D Bogaert, A van Belkum, M Sluijter, A Luijendijk… - The Lancet, 2004 - thelancet.com
A trial with a 7-valent pneumococcal-conjugate vaccine in children with recurrent acute otitis
media showed a shift in pneumococcal colonisation towards non-vaccine serotypes and an …

Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.

HE de Melker, JF Schellekens… - Emerging infectious …, 2000 - ncbi.nlm.nih.gov
We analyzed pertussis reporting, death, hospitalization, and serodiagnostic data from 1976
to 1998 to help explain the cause of the 1996 pertussis outbreak in the Netherlands. The …

Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine.

HE de Melker, MA Conyn-van Spaendonck… - Emerging infectious …, 1997 - ncbi.nlm.nih.gov
… Labadie J, Sundermann LC, Rümke HC, and the DTPIPV~Hib vaccine study group. Multi-center
study on the simultaneous administration of DTP-IPV and Hib PRP-T vaccines. Part 1. …

Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses

HC Rümke, HP Loch, K Hoppenbrouwers… - Vaccine, 2011 - Elsevier
BACKGROUND: The MMRV combination vaccine, Priorix-Tetra™, is currently licensed in
several European countries using a two-dose schedule in infants aged ≥9 months, with a …

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age

ED de Kleijn, R de Groot, J Labadie, AB Lafeber… - Vaccine, 2000 - Elsevier
To study the reactogenicity and immunogenicity of a hexavalent meningococcal outer-membrane-vesicle
vaccine (OMV), two different dosages of this vaccine (7.5 and 15 μg of …

[HTML][HTML] A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent …

TF Schwarz, J Flamaing, HC Rümke, J Penzes… - Vaccine, 2011 - Elsevier
This randomized, double-blind study evaluated concomitant administration of 13-valent
pneumococcal conjugate vaccine (PCV13) and trivalent inactivated influenza vaccine (TIV) in …

No epidemiological evidence for infant vaccinations to cause allergic disease

S Koppen, R de Groot, HJ Neijens, N Nagelkerke… - Vaccine, 2004 - Elsevier
Context: The prevalence of allergic diseases has increased considerably over the last
decades. The hygiene hypothesis has emerged, linking reduced microbial exposure and …

The nuclear symptom of schizophrenia and the praecoxfeeling

HC Rumke, J Neeleman - History of psychiatry, 1990 - journals.sagepub.com
In 1941, HC Rumke, Professor of Psychiatry in Utrecht, published his study on’The nuclear
symptom of schizophrenia and the praecoxfeeling’. The conclusion at which he arrives in this …